Zheng, Yahui Huang, Chong Lu, Lu Yu, Kangkang Zhao, Jing Chen, Mingquan Liu, Lu Sun, Qingfeng Lin, Zhifei Zheng, Jianming
...
Published in
Journal of Hematology & Oncology
BackgroundDysregulation of both mitochondrial biogenesis and mitophagy is critical to sustain oncogenic signaling pathways. However, the mechanism of mitophagy in promoting hepatocellular carcinoma (HCC) progression remains poorly understood. In this study, we investigated the clinical significance and biological involvement of mitochondrial inner ...
Liu, Yu-Chang Huang, Bo-Han Chung, Jing-Gung Liu, Wei-Lin Hsu, Fei-Ting Lin, Song-Shei
Published in
Anticancer research
Non-small cell lung cancer (NSCLC) is a serious disease and the leading cause of death globally. Overexpression of protein kinase B/nuclear factor-kappa B (NF-κB) signaling transduction of NSCLC cells was recognized as a potential therapeutic target. Lenvatinib is a multiple kinase inhibitor against vascular endothelial growth factor receptor famil...
Yokoo, Hideki Takahashi, Hiroyuki Hagiwara, Masahiro Iwata, Hiroyoshi Imai, Koji Saito, Yoshinori Matsuno, Naoto Furukawa, Hiroyuki
Published in
World Journal of Hepatology
BACKGROUND Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor reduction to make potential surgery possible. However,...
Ohya, Yuki Hayashida, Shintaro Tsuji, Akira Kuramoto, Kunitaka Shibata, Hidekatsu Setoyama, Hiroko Hayashi, Hironori Kuriwaki, Kazumi Sasaki, Masato Iizaka, Masayoshi
...
Published in
Surgical Case Reports
BackgroundLenvatinib is a novel tyrosine kinase inhibitor that exhibits an antitumor effect on hepatocellular carcinoma (HCC). An established strategy that involves surgery and usage of lenvatinib for advanced HCC remains elusive.Case presentationA 58-year-old male patient with advanced HCC and untreated hepatitis B was referred to our hospital. Th...
Suzuki, Kensuke Iwai, Hiroshi Utsunomiya, Keita Kono, Yumiko Kobayashi, Yoshiki Van Bui, Dan Sawada, Shunsuke Yun, Yasutaka Mitani, Akitoshi Kondo, Naoyuki
...
Published in
Experimental cell research
Although surgical treatment cures >90% of differentiated thyroid cancer (DTC) patients, the remaining patients, including advanced DTC cases, have poor clinical outcomes. These patients with inoperable disease have only two choices of radioactive iodine therapy and tyrosine kinase inhibitors such as lenvatinib, which have a high incidence of treatm...
Ueno, Makoto Ikeda, Masafumi Sasaki, Takashi Nagashima, Fumio Mizuno, Nobumasa Shimizu, Satoshi Ikezawa, Hiroki Hayata, Nozomi Nakajima, Ryo Morizane, Chigusa
...
Published in
BMC Cancer
BackgroundBiliary tract cancer (BTC) has a poor prognosis and lacks a standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR) 4, and platelet-derived growth factor receptor (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a known inhibitor of VEGF receptors 1–3, FGFRs 1–4, and...
Kawamura, Yusuke Kobayashi, Masahiro Shindoh, Junichi Kobayashi, Yuta Okubo, Satoshi Tominaga, Licht Kajiwara, Akira Kasuya, Kayoko Iritani, Soichi Fujiyama, Shunichiro
...
Published in
Liver Cancer
Background: The aims of this study were to evaluate the efficacy of additional treatment, especially lenvatinib-transarterial chemoembolization (TACE) sequential therapy, for unresectable hepatocellular carcinoma (HCC). Methods: Consecutive 56 patients who underwent lenvatinib treatment were reviewed. Oncological aggressiveness of tumor was estimat...
Kawanishi, Yasuhiro Kuwahara, Michio Utsunomiya, Masato Ishida, Nobuko Ishikawa, Yoichi Hiroi, Makoto Akimori, Toyokazu
Published in
Clinical journal of gastroenterology
Lenvatinib is an inhibitor of tyrosine kinases, such as vascular endothelial growth factor receptor and fibroblast growth factor receptor, and was first approved for use in thyroid cancer in 2015 in Japan. Additional approval was given in March 2018 for its use as a first-line treatment for advanced or unresectable hepatocellular carcinoma. Herein,...
Hamamoto, Takao Kono, Takashi Taruya, Takayuki Ishino, Takashi Ueda, Tsutomu Takeno, Sachio
Published in
Auris, nasus, larynx
Anaplastic thyroid carcinoma (ATC) accounts for 1-2% of all malignant thyroid tumors. There are only a small number of patients with ATC and most of them die within 6 months after diagnosis, making it difficult to establish a standard treatment strategy. Although multimodal therapy, including radical surgery, radiotherapy, and chemotherapy, has bee...
Suoh, Maito Fujii, Hideki Nagata, Yuki Kotani, Kohei Hagihara, Atsushi Enomoto, Masaru Tamori, Akihiro Inaba, Masaaki Kawada, Norifumi
Published in
Clinical journal of gastroenterology
Hypothyroidism is a common adverse event of lenvatinib therapy for hepatocellular carcinoma (HCC), whereas thyrotoxicosis has rarely been reported in clinical trials. A 74-year-old man complaining of abdominal pain was found to have liver tumors and paraaortic lymphadenopathy. The intrahepatic lesions were diagnosed as HCC by angiography and treate...
